Proof-of-Concept Safety Study of CPP-109 (Vigabatrin) for Treatment Refractory Tourette's Disorder
Status:
Completed
Trial end date:
2015-03-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to determine if vigabatrin, an unusual anti-seizure medication,
will diminish the Tourette Disorder outbursts in young adults whose symptoms have persisted
into adulthood and have not responded to usual treatment.